For how we live.
In a 134-patient phase 3 crossover trial, deucrictibant — the first oral bradykinin B2 receptor blocker — brought symptom relief in a median 1.28 hours, against more than 12 hours on placebo.
The CHMP's November meeting produced ten positive opinions. Two of them — teplizumab and a Telethon-sponsored gene therapy — address conditions the EU has had no authorised treatment for.
Sebetralstat was approved on 3 July for patients aged 12 and older. In its pivotal crossover trial, 76% of attacks treated with the 600 mg dose began to ease within 12 hours, against 49% on placebo.